Trending Now - Pfizer Pursues FDA Approval for Lyme Disease Vaccine Candidate

WHO:

Pfizer Inc.

Annaliesa Anderson, Chief Vaccines Officer at Pfizer

Valneva, Pfizer's partner in the Lyme disease vaccine development

WHAT:

Pfizer announced it will seek regulatory approval for a Lyme disease vaccine candidate.

The vaccine missed the trial's statistical goal due to insufficient cases of Lyme disease in the study.

The vaccine reduced the rate of infection by more than 70% compared to placebo.

The efficacy reported in the VALOR study was 73%.

Pfizer expects overall revenue of around $60 billion in 2026, with over $5 billion from its Covid-19 vaccine.

Valneva estimates peak annual sales of the Lyme vaccine at $1 billion.

WHERE:

The Lyme disease vaccine is relevant to the United States, particularly in the Northeast region where the disease is prevalent.

WHEN:

Pfizer made the announcement on Monday, March 23rd, 2026.

The Phase 3 trial initially enrolled about 18,000 participants but ended with about 9,400 after dropping half due to quality concerns in 2023.

WHY:

The vaccine aims to protect against Lyme disease, which affects about half a million Americans annually, according to the Centers for Disease Control and Prevention.

Pfizer views the vaccine results as a major catalyst for the company in 2026.

HOW:

The vaccine targets the outer surface protein A of the bacteria that cause Lyme disease.

The vaccination series involves three shots in the first year, followed by a booster dose the following year.

No safety concerns were observed in the trial.

(UPDATED March 23, 2026 17:52 UTC)

Pfizer announced on Monday that it will seek regulatory approval for a Lyme disease vaccine candidate, which demonstrated a 73% efficacy rate in reducing infection compared to a placebo, despite missing its trial's statistical goal due to insufficient cases. The vaccine, developed in partnership with Valneva, aims to protect against Lyme disease, which affects about half a million Americans each year, particularly in the Northeast. Pfizer expects significant revenue from this vaccine, with Valneva estimating peak annual sales could reach $1 billion, as the company anticipates overall revenue of around $60 billion in 2026.